Island Pharmaceuticals Ltd · ASX:ILA

Island Pharmaceuticals — Investor Presentation (November 2026)

21 slides from Island Pharmaceuticals's investor presentation, Nov 17, 2026

  1. Slide 1: Combatting Urgent Viral Disease Threats

    For personal use only COMBATTING URGENT VIRAL DISEASE THREATS Dr David Foster, CEO & Managing Director Mr Jason Carroll, Non-Executive Chairman ASX: ILA November 2026

  2. Slide 2: Disclaimer

    DISCLAIMER For personal use only Important Information This disclaimer applies to this presentation and the information contained in it (Presentation). By reading this disclaimer you agree to be bound by it. The Presentation has been prepared by Island Pharmaceuticals Limited and all related bodies

  3. Slide 3: Company Overview

    Company Overview For personal use only Shares on issue¹: 296,096,682 Substantial shareholders Price per share¹: $0.295 Dr William James Garner³ 13.67% Market capitalisation¹: $87.35m Cash at bank (30 June 2026)²: $7.83m Jason Alan Carroll³ 10.84% Potential additional capital from vested options MWP

  4. Slide 4: Company overview and investment thesis

    Company overview and investment thesis For personal use only Highlights Defined investment case with near term upside potential 01 Imminent Marburg-Angola NHP study Two, well advanced clinical stage programs with A controlled study intended to inform effective dose selection and broad acting antivir

  5. Slide 5: The Filovirus Threat Landscape: An urgent and growing global challenge

    The Filovirus Threat Landscape: Heading An urgent and growing global challenge For personal use only Extremely high fatality rates Limited BSL-4 pathogens Highest recorded case fatality rate by virus countermeasures Require maximum containment; limited 90% 88% No approved therapeutics or vaccines fo

  6. Slide 6: Galidesivir: a broad-spectrum antiviral

    Heading Galidesivir: a broad-spectrum antiviral Activity against over 20 RNA viruses and efficacy in non-human primates infected with Marburg and Ebola For personal use only 20+ Mechanism Adenosine nucleoside analogue that blocks the viral RNA polymerase, stopping RNA viruses where Galidesivir shows

  7. Slide 7: Rapid clinical and operational progress

    Rapid clinical and operational progress Acquisition to the commencement of NDA-related studies in 15 months For personal use only Sep 2024 Aug 2025 Dec 2025 May 2026 Jul 2026 Nov 2026 LOI signed with BioCryst FDA Type C meeting – US patent granted for Bundibugyo Ebola – Uganda Ebola NHP surgeries co

  8. Slide 8: Marburg NHP Survival

    Marburg NHP Survival 94% survival in Marburg (Musoke) NHP Model with treatment initiated up to 48 hours post-infection For personal use only This level of efficacy, with a clinically meaningful therapeutic window, is rare in filovirus models and directly supports Animal Rule advancement Island Pharm

  9. Slide 9: FDA Animal Rule vs Traditional development pathway

    FDA Animal Rule VS Traditional development pathway For personal use only Traditional drug development ~9–15 years NDA Discovery & preclinical Phase 1–3 clinical trials 4–8 years 4–6 years review ~1 year Animal Rule: Galidesivir for Marburg ~10 months to pivotal readout NHP efficacy NDA Discovery & p

  10. Slide 10: FDA Animal Rule: A proven development pathway

    FDA Animal Rule: A proven development pathway For personal use only Why animal efficacy data are central to Marburg countermeasure development Why the Animal Rule matters Evidence must be integrated Human efficacy trials may be unethical or Animal efficacy, human safety, pharmacokinetic infeasible f

  11. Slide 11: Animal Rule is a proven path for SNS inclusion

    Animal Rule is a proven path for SNS inclusion For personal use only ➢ Since 2012, the FDA’s Animal Rule approval has led to 8 bioterror countermeasures joining the US Strategic National Stockpile (SNS) ➢ In 7 out of 8 cases, these medical countermeasures continue to remain under SNS contract and ha

  12. Slide 12: Path to the Pivotal

    Path to the Pivotal For personal use only Two-phase NHP studies to define dose, treatment window and pivotal design Time of treatment 1 Dose-response 2 3 Pivotal efficacy study initiation • Defines the effective dose • Defines the treatment window • Informed by Studies 1 & 2 • Blinded; dosing starts

  13. Slide 13: What will the imminent dose-escalation study tell us?

    What will the imminent dose-escalation study tell us? A decision-making milestone — not a registration study on its own For personal use only Survival and consistency Dose-response evidence Assess survival outcomes against the control group Evaluate whether the results support a scientifically and c

  14. Slide 14: Ebola NHP Survival

    Ebola NHP Survival Robust efficacy in Zaire Kikwit NHP model with delayed dosing For personal use only Survival of rhesus non-human primates (6 per arm) challenged with Ebola virus (10³) followed 2 or 3 days later by intramuscular administration of 100 mg/kg BID loading dose + 25 mg/kg BID for 10 da

  15. Slide 15: Cumulative Ebola cases and deaths in current vs past outbreaks

    Cumulative Ebola cases and deaths in current vs past outbreaks For personal use only 11,073 5,391 ~49% #2 largest Ebola outbreak on confirmed cases to date confirmed deaths to date case fatality rate (confirmed) record Cumulative confirmed cases Cumulative confirmed deaths 12,000 11,073 6,000 5,391

  16. Slide 16: Government-Approved Africa Protocol

    Government-Approved Africa Protocol Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework For personal use only Government approvals have been secured to evaluate Galidesivir in Uganda in under the WHO MEURI framework, creating a unique opportunity to generate p

  17. Slide 17: Near-Term Catalysts

    Near-Term Catalysts A number of value catalysts pending in the coming months For personal use only Milestone Timeframe Establish Fellows Program to provide expert access to strategic subject matter KOLs Complete FDA feedback on Galidesivir protocol clarifying questions Received Government-approved d

  18. Slide 18: Thank You

    For personal use only THANK YOU dfoster@islandpharmaceuticals.com Investor relations: +1 510-393-6523 Henry Jordan, Six Degrees Investor Relations islandpharmaceuticals.com +61 (0) 431 271 538 @IslandPharma henry.jordan@sdir.com.au Island Pharmaceuticals ASX: ILA

  19. Slide 19: Marburg Virus – Where Antivirals Act

    Marburg Virus – Where Antivirals Act Key viral targets and the mechanism of Galidesivir For personal use only Island Pharmaceuticals Limited 18

  20. Slide 20: Broad-spectrum Antiviral Effects Including Filovirus

    Broad-spectrum Antiviral Effects Including Filovirus For personal use only Adjusted EC50 Virus Family Virus Strain/Variant Assay Cell Cell Type EC50 (µM) CLE (µM) Marburg Musoke HCI HeLa 4.4 35% 1.5 Marburg Ci67 HCI HeLa 6.7 35% 2.3 Filoviridae Marburg Angola HCI HeLa 5 35% 1.8 Ebola Zaire (Kikwit)

  21. Slide 21: FDA Response Significantly De-risks Regulatory Pathway

    FDA Response Significantly De-risks Regulatory Pathway For personal use only FDA confirmed the Clear guidance FDA advised that Island intends to Animal Rule provided on clinical Galidesivir would commence the next pathway is program design – qualify for a Tropical Galidesivir animal appropriate for

Island Pharmaceuticals — Investor Presentation (November 2026) on 6ix